Every-other-day interferon β-1b versus once-weekly interferon β-1a for multiple sclerosis: results of a 2-Jahr prospective randomised multicentre study (INCOMIN). - Durelli,L.; Verdun,E.; Barbero,P. (Lancet, 2002)